Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers, particularly through its product, bexmarilimab, targeting the Clever-1 receptor.

Faron Pharmaceuticals Ltd.

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

COM:FARON

Faron Pharmaceuticals Ltd.

Last Close

142.50

22/11 14:00

Market Cap

1.36M

Beta: -

Volume Today

20.05K

Avg: -

Filings Not Available